Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology

Life Sciences Talent Network Shaping Future Leaders in NJ’s Biotech Industry

Trenton, NJ, August 16, 2017Matt Alcalde, Director of Life Sciences Talent Network at BioNJ, writes:

Now in its second year, the Life Sciences Talent Advisory Board, managed by the Life Sciences Talent Network at BioNJ, has engaged over 100 employers from New Jersey’s robust health and life sciences industry.

These employers include pharmaceutical, biotechnology and medical device companies that are researching and developing new drugs and therapies to treat various diseases affecting patients worldwide as well as others who are supporting that work. Continue reading

Commercial Center for Innovative Technologies Adds Genomic Prediction, A Startup Fertility Treatment Company

North Brunswick, NJ, August 3, 2017 — Vince Calio reports in NJBIZ that the Commercial Center for Innovative Technologies has a new addition to its family, as Genomic Prediction, a startup fertility treatment company, has moved into the space — and is growing already.

The company was co-founded by Rutgers University associate professor Nathan Treff, and specializes in testing human embryos for a range of chromosomal abnormalities and genetic disorders before they are implanted in women who are seeking in vitro fertilization to become pregnant.

So far, the company’s long-term focus is on developing polygenic tests to predict the risk of diabetes and other conditions. Continue reading

Choose New Jersey CEO Michele Brown: ‘Access to Lab Space, Funding and Partners Help Biotech Companies Grow in Garden State’

Michele Brown (Photo: NJBIZ/Aaron Houston)

Trenton, NJ, August 1, 2017Choose New Jersey, Inc. led a delegation representing more than 20 New Jersey organizations — including top life sciences companies, universities, trade associations, state officials — as it showcased New Jersey’s assets and resources for biotechnology companies at BIO International 2017, which was June 19-22 in San Diego, California. 

Prior to the BIO event, Choose New Jersey President and Chief Executive Officer Michele Brown in June wrote:

When Hurel Corporation outgrew its incubator space at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick, New Jersey in 2016, it marked an important milestone for the biotechnology company. Continue reading

BIO Report Finds Bioscience Drives Economic Growth in States Across U.S.

Washington, DC, July 10, 2017 — A new report from Biotechnology Innovation Organization (BIO) concludes that the bioscience industry has had a positive impact on states’ economies and continues to be a driver of economic growth.

According to the new BIO report released in June, state lawmakers have recognized the importance of the industry, the authors state, and have responded to challenges facing the bioscience companies with legislative efforts focused on a supportive business climate. Continue reading

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

Opinion: Assemblyman Gary Schaer on ‘A Blueprint for Tomorrow’

Asm. Gary Schaer

Trenton, NJ, June 20, 2017Assemblyman Gary S. Schaer (D-Passaic), Chair of the Assembly Budget Committee, last month shared the following with Innovation New Jersey readers:

Each time we tackle the state budget, we are reminded that it is a living, breathing document that, at its core, should fundamentally reflect our priorities.  As we enter final deliberations in crafting this year’s state budget, that reminder is all the more potent.

One of the reasons New Jersey’s economy lagged far behind most of the nation after the Great Recession is because we failed to make the proper investments to capitalize on our strengths and leverage our assets to grow our economy.  We cannot expect to move forward and grow as a state without planting the proper seeds.  Continue reading

Opinion: Former Merck CEO and Princeton University President Emeritus on ‘Trump’s War on Science Threatens U.S. Prosperity’

Princeton, NJ, June 12, 2017Roy Vagelos, retired Chairman and CEO of Merck & Co. and Chairman of the Board of Regeneron Pharmaceuticals, and Shirley Tilghman, President Emeritus of Princeton University and a professor of Molecular Biology and Public Affairs, published the following opinion piece in The Star-Ledger on June 6:

In the past 40 years, the U.S. has been the world leader in converting fundamental scientific discoveries into innovative new treatments for life-threatening disease.  New drugs, vaccines, and medical devices have improved human health and increased our lifespan. Continue reading

HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego

New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.

Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading